Are Oil and Gas Companies Leveraging ESG Strategies Enough?

 

Key Points:

  • Oil and gas companies are starting to center ESG strategies.
  • They are using these strategies for future investments.
  • There has been a lot of effort from companies to embrace sustainability.

Commentary:

It is no mystery that the world is trying to become more green in its energy usage. Oil and gas companies are starting to center ESG strategies for future investments, and right now, there seems to be a lot of available capital on the surface. Are enough resources being put into green transition efforts as a whole, though? We sourced Jimmy Jett, CEO of Integrity Biochem, for perspectives. He breaks down not only his take on the energy industry’s sustainable investments, but how

To act as a stopgap while technologies like wind and solar generation gain enough investment to be a viable and scalable energy alternative, companies are turning to individual products to improve smaller portions of their carbon footprint. Even with a hot market for green energy products ready for new business, what about the companies who want to take green technology to market but just aren’t producing enough capital? What sort of strategies could they implement to make their product more commercially viable without reducing the quality or green impact?

Abridged Thoughts:

I think you’re seeing a solid effort made by the industry, especially on the sustainability side. It’s tricky because there’s been a lot of capital that has been pulled back after the last downturn. You’re starting to see a lot more money in your end of the market, as the industry kind of realizes that there’s a lag between eliminating oil and gas in the energy pipeline as opposed to improving the way it’s produced.   

And so I think you’re going to see more money put into it. But as a percentage, I would say that all the companies that we work with in the space are very dedicated to sustainability efforts, and it’s good to see. But as capital comes back into the energy space, I think you’re going to see a more focused effort. Energy is always going to be a point of discussion because it’s what the world runs on. 

More Stories Like This:

Chevron CEO Mike Worth on ESG Investing and Oil’s Climate Solution Role

Fossil Fuel 2030 Reduction Goal Not Expected to Be Met

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More